Introduction
Chronic myelocytic leukaemia (C.M.L.) is usually characterized by the Philadelphia (Ph') chromosome in cells of myeloid origin. With rare exceptions' this is a constant feature, being found in overt disease, during excellent clinical and haematological remissions, and in the terminal stages. Ph'-positive cells may become established in the spleen2 3 and other extramedullary sites. 4 In some patients the Ph' chromosome is the only karyotypic abnormality detectable throughout the course of the disease. Additional cytogenic abnormalities, however, may appear as the patient enters the terminal stage. These include changes in the number of chromosomes, the appearance of "marker" chromo- 5 6 Occasionally such aberrations appear before any clinical or haematological deterioration is apparent; if so, they are of serious prognostic import. There is an increasing body of evidence that haematological deterioration and death in C.M.L. results from the proliferation of one or more increasingly abnormal clones of leukaemic cells, and that the karyotypic abnormalities seen in the terminal phase constitute overt evidence of this process.
We report the case of a patient who underwent splenectomy in the "terminal phase" of C.M.L. and whose subsequent course suggested that this procedure eliminated the abnormal clone of cells responsible for his deteriorating haematological condition.
Case Report A 32-year-old black steel worker was diagnosed in March 1968 as a case of C.M.L. after bleeding profusely following a tooth extraction. His W.B.C. was 247 x 109/1 (65% neutrophils, 2% lymphocytes, 1% eosinophils, 2% basophils, 12% myelocytes, 17% promyelocytes, 1% myeloblasts); platelets were 110 x 109/1; and haemoglobin was 11 g/dl. His spleen extended 17 cm below the costal margin and he had subcutaneous nodules 2 cm in diameter in both thighs. Appearances on bone marrow and splenic biopsy were consistent with the diagnosis; no fibrosis was seen in the biopsy specimen. Aspiration of the subcutaneous nodules yielded myelocytes and normoblasts. Leukocyte alkaline phosphatase score was zero. Chromosomal analysis of bone marrow cells revealed the Ph' chromosome but no other abnormalities.
The patient was included in a comparative study of mitobronitol and busulphan. His initial treatment was with mitobronitol, which decreased the W.B.C. and spleen size but caused pronounced thrombocytopenia requiring transfusions. He was then treated with busulphan from July to November 1968. This induced a good remission except for the development of recurrent thrombocytopenia. The haemoglobin and W.B.C. became normal and the spleen impalpable. Subsequently he received maintenance therapy with mitobronitol. His course was complicated by thrombocytopenia, which required frequent discontinuance of the drug or reduction of the dose, producing wide fluctuations in the W.B.C. Nevertheless, the haemoglobin remained normal, the spleen was not felt, and differential counts showed no blasts or promyelocytes.
In February 1970 recurrent splenomegaly was noted and mitobronitol was abandoned. Treatment with cytarabine, carmustine, busulphan, and cyclophosphamide failed to re-establish stable control; modest numbers of blasts and promyelocytes appeared in the peripheral blood, the haemoglobin fell to 11-12 g/dl, and the spleen increased in size. Blasts in a marrow aspirate, however, remained below 5%. On 24 September the spleen extended 21 cm below the costal margin, the W.B.C. was 129 x 109/1 (2% blasts, 3% promyelocytes), and the platelets were 32 x 109/1. A bone marrow aspirate was reported as showing "early myeloblastic transformation" (blasts 15-4%, promyelocytes 21-6%) and the patient was referred to us. He was given loading doses of hydroxyurea (0 05 g/ kg) to control the rising W.B.C., and on 29 September splenectomy was performed. The spleen (which had decreased in size with hydroxyurea) weighed 1800 g and contained many immature myeloid cells and a few normoblasts but no megakaryocytes. The postoperative course was uneventful and the platelet count rose to over 200 x 109/1.
The patient was then treated with a demecolcine-mercaptopurine combination7 and entered an immunotherapy programme for C.M.L.8 An excellent remission was achieved and he remained in a good haematological and clinical condition for almost three years in a programme of "rotating" maintenance chemotherapy with two-drug combinations. In June 1973 routine bone marrow aspiration showed aneuploidy but an otherwise normal marrow. Five weeks later immature cells were detected in the peripheral blood and bone marrow aspiration showed 17-6% myeloblasts. His haematological and clinical condition deteriorated rapidly, with anaemia, thrombocytopenia, fever, subcutaneous nodules, and bone pain. He fig. 1) . The splenic karyotype, however, was grossly abnormal. All 22 mitoses examined contained a submetacentric marker chromosome replacing a chromosome of group C (6-12). In addition some mitoses contained an abnormality of the second G-22 chromosome, which appeared as a smudge ( fig. 2) Possibly these may have been of splenic origin, containing the abnormal karyotype, and were eliminated by the brief but effective course of hydroxyurea before splenectomy. If so, one would assume that the marrow had not then been colonized by the abnormal clone. It appears highly unlikely that so short a course of hydroxyurea would have had a permanent effect on an established population of cells in marrow while leaving the splenic clone easily demonstrable. Large numbers of neoplastic cells may enter the marrow from other sites without establishing a proliferating population there. We have seen four patients with disseminated lymphoproliferative disease9 and one with "blastic" myeloid metaplasia of the spleen (unpublished data) in whom marrow remission followed local radiation therapy or splenectomy.
Aggressive treatment of myeloblastic transformation may temporarily eliminate clones of leukaemic cells with karyotypic abnormalities,'0 but such remissions are usually short-lived and the abnormal karyotype often recurs within weeks." In our patient, in contrast, the abnormal clone of cells shown in the spleen disappeared permanently after splenectomy. Karyotypic abnormalities were again found during the last six months of life, but these were different from those seen originally. Nevertheless, cytogenetic examination on 29 June 1973, when the patient appeared to be in complete remission of leukaemia, predicted the rapid haematological and clinical deterioration that was observed a few weeks later.
Attempts to reverse the terminal episode of myeloblastic transformation were unsuccessful. This is consistent with our experience that Ph'-positive patients who develop additional karyotypic abnormalities are much more refractory to treatment of the blastic state than patients who retain the original chromosomal pattern.
We showed frequent premature ventricular ectopic beats, paroxysmal ventricular tachycardia, and ST-T wave changes; haemoglobin was 13-1 g/dl; W.B.C. 7-6 x 
